Combined Unilateral Subthalamic Nucleus and Contralateral Globus Pallidus Interna Deep Brain Stimulation for Treatment of Parkinson Disease: A Pilot Study of Symptom-Tailored Stimulation.
Deep brain stimulation
Globus pallidus interna
Parkinson disease
Subthalamic nucleus
Symptom-tailored
Journal
Neurosurgery
ISSN: 1524-4040
Titre abrégé: Neurosurgery
Pays: United States
ID NLM: 7802914
Informations de publication
Date de publication:
16 11 2020
16 11 2020
Historique:
received:
10
09
2019
accepted:
19
03
2020
pubmed:
28
5
2020
medline:
6
1
2022
entrez:
28
5
2020
Statut:
ppublish
Résumé
Subthalamic nucleus (STN) and globus pallidus interna (GPi) are the most effective targets in deep brain stimulation (DBS) treatment for Parkinson disease (PD). However, the individualized selection of targets remains a clinical challenge. To combine unilateral STN and contralateral GPi stimulation (STN DBS in one brain hemisphere and GPi DBS in the other) to maximize the clinical advantages of each target while inducing fewer adverse side effects in selected patients with PD because each target has its own clinical effects and risk profiles. We reviewed the clinical outcomes of 8 patients with idiopathic PD treated with combined unilateral STN and contralateral GPi DBS. Clinical outcome assessments, focusing on motor and nonmotor symptoms, were performed at baseline and 6-mo and 12-mo follow-up. We performed the assessments under the following conditions: medication on and off (bilateral stimulation on and off and unilateral STN stimulation on). Patients showed a significant improvement in motor symptoms, as assessed by the Unified Parkinson Disease Rating Scale III (UPDRS-III) and Timed Up-and-Go Test (TUG), in the off-medication/on-stimulation state at 6-mo and 12-mo follow-up. Also, patients reported a better quality of life, and their intake of levodopa was reduced at 12-mo follow-up. In the on-medication condition, bilateral stimulation was associated with an improvement in axial symptoms, with a 64% improvement in measures of gait and falls at 12-mo follow-up. No irreversible adverse side effects were observed. Our findings suggest that combined unilateral STN and contralateral GPi DBS could offer an effective and well-tolerated DBS treatment for certain PD patients.
Sections du résumé
BACKGROUND
Subthalamic nucleus (STN) and globus pallidus interna (GPi) are the most effective targets in deep brain stimulation (DBS) treatment for Parkinson disease (PD). However, the individualized selection of targets remains a clinical challenge.
OBJECTIVE
To combine unilateral STN and contralateral GPi stimulation (STN DBS in one brain hemisphere and GPi DBS in the other) to maximize the clinical advantages of each target while inducing fewer adverse side effects in selected patients with PD because each target has its own clinical effects and risk profiles.
METHODS
We reviewed the clinical outcomes of 8 patients with idiopathic PD treated with combined unilateral STN and contralateral GPi DBS. Clinical outcome assessments, focusing on motor and nonmotor symptoms, were performed at baseline and 6-mo and 12-mo follow-up. We performed the assessments under the following conditions: medication on and off (bilateral stimulation on and off and unilateral STN stimulation on).
RESULTS
Patients showed a significant improvement in motor symptoms, as assessed by the Unified Parkinson Disease Rating Scale III (UPDRS-III) and Timed Up-and-Go Test (TUG), in the off-medication/on-stimulation state at 6-mo and 12-mo follow-up. Also, patients reported a better quality of life, and their intake of levodopa was reduced at 12-mo follow-up. In the on-medication condition, bilateral stimulation was associated with an improvement in axial symptoms, with a 64% improvement in measures of gait and falls at 12-mo follow-up. No irreversible adverse side effects were observed.
CONCLUSION
Our findings suggest that combined unilateral STN and contralateral GPi DBS could offer an effective and well-tolerated DBS treatment for certain PD patients.
Identifiants
pubmed: 32459849
pii: 5847859
doi: 10.1093/neuros/nyaa201
pmc: PMC7666906
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1139-1147Informations de copyright
© Congress of Neurological Surgeons 2020.
Références
JAMA Neurol. 2018 Mar 1;75(3):367-372
pubmed: 29356826
Lancet Neurol. 2012 Feb;11(2):140-9
pubmed: 22239915
Parkinsonism Relat Disord. 2011 Dec;17(10):745-8
pubmed: 21856205
Neurosurgery. 2018 Jun 1;82(6):753-756
pubmed: 29538685
Nat Rev Neurosci. 2006 Feb;7(2):160-6
pubmed: 16429125
N Engl J Med. 2001 Sep 27;345(13):956-63
pubmed: 11575287
Surg Neurol Int. 2017 Oct 24;8:261
pubmed: 29184712
Neurology. 2015 Mar 31;84(13):1355-61
pubmed: 25724233
J Neurosurg. 2018 Nov 1;:1-6
pubmed: 30497175
Mov Disord. 2009 Mar 15;24(4):557-63
pubmed: 19097175
Neuromodulation. 2016 Jan;19(1):31-7
pubmed: 26568568
N Engl J Med. 2010 Jun 3;362(22):2077-91
pubmed: 20519680
Mov Disord. 2017 Jan;32(1):36-52
pubmed: 28124435
J Neurosurg. 2010 Dec;113(6):1224-9
pubmed: 20849215